Catalyst Wire Dossier Catalyst Wire Dossier

CAP-002 gene therapy

· Capsida Biotherapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAP-002 gene therapy, covering 2025-10-01 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy [Phase 1, Phase 2]

See pricing